Diagnosing Lung Adenocarcinoma

Symptoms and Advances in Cancer Treatment

In This Article
Table of Contents

Lung adenocarcinoma is a form of non-small cell lung cancer, the most common type of lung cancer. Non-small cell lung cancers account for 80% of lung malignancies, and of these, roughly 50% are adenocarcinomas.

Adenocarcinoma is today the most common form of lung cancer in women, Asians, and people under the age of 45. Confoundingly, it is more likely to strike non-smokers (either never smokers or former smokers) than people who currently smoke.

While the rate has been decreasing in men and leveling off in women, the numbers continue to rise in young, nonsmoking women, and we're not entirely sure why. It is largely believed that genetics, secondhand smoke, and exposure to radon in the home are all contributing factors, but the reasons are still uncertain. Unfortunately, due to the stigma of lung cancer being a smoker's disease, less research into the possible causes is lacking.

lung adenocarcinoma symptoms
Illustration by JR Bee, Verywell


Lung adenocarcinomas usually begin in tissues near the outer portion of the lungs and may be there for a long time before symptoms appear. When they finally appear, the signs are often less obvious than other forms of lung cancer, manifesting with a chronic cough and bloody sputum only in later, more advanced stages.

Because of this, some of the more generalized, early symptoms (such as fatigue, subtle shortness of breath, or upper back and chest pain) may be missed or attributed to other causes. As a result, diagnoses are often late, particularly among young people and non-smokers who may have never considered cancer as a threat.


Lung cancer is often first detected when abnormalities are seen on an X-ray, usually in the form of a poorly defined shadow. While distressing, the finding at least offers the opportunity for early diagnosis. In as many as 25% of lung cancer cases, a chest X-ray will not detect any irregularities and return a perfectly "normal" diagnosis.

If cancer is suspected, other, more sensitive diagnostics may be used, including:

Again, it should be emphasized that a chest x-ray alone cannot rule out a diagnosis of lung cancer, and if there are any concerns at all, further studies should be done.

Sputum cytology, in which a sample of coughed up saliva and mucus are evaluated, may also be used but is considered less useful in diagnosing early cancer.

Depending upon the results, your doctor may want to obtain a sample of lung tissue to confirm the diagnosis. In addition to more invasive lung tissue biopsies, a newer blood test called a liquid biopsy may be able to follow specific genetic abnormalities in lung cancer cells such as EGFR mutations.

Genetic Profiling

One of the more exciting advances has been the use of genetic testing to profile cancer cells. By doing so, doctors can select treatments able to target those specific genetic variants. This targeted approach is far less generalized than earlier generation treatments which broadly attacked both healthy and unhealthy cells, resulting in severe and even intolerable side effects.

Current guidelines recommend that all persons with advanced or metastatic lung adenocarcinoma be genetically tested and have PD-L1 testing to profile their specific cancer.

Specific treatments are available not only for those who have EGFR mutations, ALK rearrangements, and ROS1 rearrangements, but BRAF, ERBB2, MET splice mutations and amplifications, RET rearrangements, and more. In addition, clinical trials are in process looking at further mutations and targeted therapies.

PD-L1 Testing and Tumor Mutation Burden

PD-L1 testing is done in order to predict the potential effectiveness of the four immunotherapy drugs now approved for lung cancer. Discussing your molecular testing and PD-L1 testing is one of the most important steps when you are first diagnosed with advanced lung adenocarcinoma, as this area is rapidly changing. For example, the first immunotherapy drug for lung cancer was approved in 2015. PD-L1 testing is far from perfect in predicting who will, and who will not, respond to these drugs. Other tests, such as tumor mutation burden (the number of mutations present in a tumor) may also help to understand who will most benefit from these drugs.


Once a cancer diagnosis is confirmed, the doctor will stage the disease based on a series of standard tests. The aim of staging is to determine how advanced the cancer is, whether it has spread, and what, if any, other tissues may be involved. Staging helps direct treatment in a more appropriate manner, neither undertreating a malignancy or overtreating in and causing more harm than good.

The four stages are classified as follow:

  • Occult lung cancer: An occult lung cancer is considered to be present if cancer cells are found in sputum but a tumor cannot be found in the lungs by imaging studies.
  • Stage 0: The cancer is not yet invasive, but is rather carcinoma-in-situ.
  • Stage 1: The cancer is localized and has not spread to any lymph nodes. This is the earliest stage of "invasive" lung cancer.
  • Stage 2: The cancer has spread to lymph nodes, the lining of the lungs, or the major passageways of the lungs.
  • Stage 3: The cancer has spread to nearby tissue. Stage 3 is again broken down into stage 3A, stage 3B, and stage 3C, which all behave, and are treated, very differently.
  • Stage 4: The cancer has spread (metastasized) to other regions of the body or there is a malignant pleural effusion. Lung cancer metastasizes most often spreads to the bones, brain, liver, and adrenal glands.

When learning about treatment options you are likely to hear of lung cancer being defined in a one of the following ways:

  • Early stage lung cancer: The term early stage is used to describe lung cancers which are stage 1 or stage 2. These are tumors which are potentially curable with surgery.
  • Locally advanced lung cancer: This term is most often used to describe cancers which are stage 3A. Surgery may be possible, but adjuvant treatment with chemotherapy and radiation therapy is usually required to control the tumor.
  • Advanced lung cancer: The term advanced lung cancer is often used for stage 3B and stage 4 cancers, and is a stage at which non-surgical treatments are the best option.

Treatment Options

Depending upon the stage of disease, treatment may include one or a combination of the following:

  • Surgery may be offered in the early stages, either alone or accompanied by chemotherapy and/or radiation therapy. When successful, surgery offers the best chance of curing a lung cancer.
  • Chemotherapy may be used alone, in conjunction with radiation therapy, or before or after surgery.
  • Targeted therapies are medications designed to attack specific genetic mutations. They work by recognizing specific proteins on cancer cells and blocking the cell's ability to replicate. Options include Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), Xalkori (crizotinib), Zykadia (ceritinib), Alecnensa (alectinib), and Tagrisso (osimertinib).There are also many more options available in clinical trials.
  • Radiation therapy may be used either to treat cancer or to control symptoms in those with metastatic cancer. More targeted forms of treatment, known as stereotactic body radiotherapy (SBRT), or proton therapy may be used for smaller cancers which surgery cannot reach. SBRT is now also being used to treat metastases (such as brain metastases) in people with lung cancer, when only a few metastases are present.
  • Immunotherapy is a form of treatment which aims to harness the body's immune system to fight cancer. Current options include Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab) and Imfinzi (durvalumab) for stage 3 and 4 lung cancer.
  • Clinical trials are the only way that newer treatments can be evaluated for the treatment of lung cancer, and the National Cancer Institute recommends that people with lung cancer consider taking part in a clinical trial. In the past, the likelihood that a clinical trial would make a difference for an individual was small, but this is changing rapidly as specific targets in the pathway of cancer cell division are understood. Many people living with stage 4 lung cancer at this time are only alive because of their participation in a clinical trial.

A Word From Verywell

Because the early symptoms of lung cancer are often difficult to spot, the average five-year survival rate is only around 18%. For those diagnosed in the early stages, the outlook is far more promising.

What this highlights is the need for greater awareness about the nonspecific or atypical symptoms of lung cancer. On their own, the symptoms may be easy to miss. Together, they may trigger a red flag that can lead to both early diagnosis and earlier, more effective treatment.

The treatment of lung adenocarcinoma is improving rapidly and survival rates are improving as well. In some cases, even advanced tumors can be kept in check for quite some time with targeted therapies. For a smaller percentage of people with stage 4 lung cancer, immunotherapy treatments have resulted in a "durable response" meaning the disease has stabilized and not progressed for a period of months. With the complexity of molecular findings, it's very helpful to find an oncologist who specializes in lung cancer. Many physicians recommend getting a second opinion from another doctor or one of the National Cancer Institute designated treatment centers, centers that have specialists who only treat lung cancer and are actively involved in research looking at newer and better treatments. It's also critically important to be your own advocate in your cancer care.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Cancer Support Community. Non-small cell lung cancer. 2019.

  2. University of Texas Southwestern Medical Center at Dallas. Researchers Uncover Mutated Genes Involved In Lung Cancer; One Affects Nonsmokers. 2005.

  3. American Cancer Society. Facts & Figures 2018: Rate of Deaths From Cancer Continues Decline. 2018.

  4. American Cancer Society. What Causes Lung Cancer? Updated October 1, 2019.

  5. American Cancer Society. Signs and Symptoms of Lung Cancer. Updated October 1, 2019.

  6. Del Ciello A, Franchi P, Contegiacomo A, Cicchetti G, Bonomo L, Larici AR. Missed lung cancer: when, where, and why? Diagn Interv Radiol. 2017;23(2):118-126. doi:10.5152/dir.2016.16187

  7. American Cancer Society. Tests for Lung Cancer. Updated October 1, 2019.

  8. O'Malley DP, Yang Y, Boisot S, et al. Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases. Mod Pathol. 2019;32(7):929-942. doi:10.1038/s41379-019-0210-3

  9. Zhuang X, Zhao C, Li J, et al. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Cancer Med. 2019;8(6):2858-2866. doi:10.1002/cam4.2183

  10. American Cancer Society. Immune Checkpoint Inhibitors and Their Side Effects. Updated December 27, 2019.

  11. American Cancer Society. Non-Small Cell Lung Cancer Stages. Updated October 1, 2019.

  12. American Cancer Society. Treatment Choices for Non-Small Cell Lung Cancer, by Stage. Updated October 1, 2019.

  13. American Cancer Society. Radiation Therapy for Non-Small Cell Lung Cancer. Updated October 1, 2019.

  14. American Cancer Society. Immunotherapy for Non-Small Cell Lung Cancer. Updated October 1, 2019.

  15. National Cancer Institute. Treatment Clinical Trials for Non-Small Cell Lung Cancer. 2019.

  16. American Lung Association. Lung Cancer Fact Sheet. Updated September 25, 2019.

  17. Tamminga M, De Wit S, Hiltermann TJN, et al. Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. I Immunother Cancer. 2019;7(1):173. doi:10.1186/s40425-019-0649-2

Additional Reading